MERTK and neoplasm: The MerTK‐expressing TAMs could transfer into pro‐tumor M2 phenotype upon stimulation by apoptotic materials.[226] More importantly, M2‐like macrophages express much higher MerTK and exhibit stronger capability of efferocytosis than M1‐like macrophages.[230] Therefore, blocking PtdSer exposed by dying/apoptotic tumor cells and MerTK activation to blunt macrophage‐mediated efferocytosis could be a promising method for alleviating the immunosuppressive TME via reversing the anti‐inflammatory M2‐like TAMs.